tirzepatide cvot SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized Frontiers | Tirzepatide's innovative applications

This comprehensive evaluation allows our affiliated prescribing providers to review your full medical history, including all current medications and health conditions

Semaglutide is a GLP-1 receptor agonist originally developed to treat type 2 diabetes, which has also been found effective for weight loss by regulating appetite and reducing food intake

Because metabolism and immunity are linked, improving your metabolic health can have positive, indirect benefits for your immune system

While numerous studies have investigated the effects of various antidiabetic therapies on diabetes-related ED, the results remain inconsistent, limiting definitive conclusions

Clinicians may monitor pancreatic enzymes or review risk factors if symptoms arise

Incretins are hormones sent from the gut to the brain